These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 32068780)

  • 21. Enhanced JunD/RSK3 signalling due to loss of BRD4/FOXD3/miR-548d-3p axis determines BET inhibition resistance.
    Tai F; Gong K; Song K; He Y; Shi J
    Nat Commun; 2020 Jan; 11(1):258. PubMed ID: 31937753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
    Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
    Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
    Mu X; Bai L; Xu Y; Wang J; Lu H
    Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Embryonic Program Activated during Blast Crisis of Chronic Myelogenous Leukemia (CML) Implicates a TCF7L2 and MYC Cooperative Chromatin Binding.
    Desterke C; Hugues P; Hwang JW; Bennaceur-Griscelli A; Turhan AG
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma.
    Wong M; Sun Y; Xi Z; Milazzo G; Poulos RC; Bartenhagen C; Bell JL; Mayoh C; Ho N; Tee AE; Chen X; Li Y; Ciaccio R; Liu PY; Jiang CC; Lan Q; Jayatilleke N; Cheung BB; Haber M; Norris MD; Zhang XD; Marshall GM; Wang JY; Hüttelmaier S; Fischer M; Wong JWH; Xu H; Perini G; Dong Q; George RE; Liu T
    Nat Commun; 2019 Jul; 10(1):3319. PubMed ID: 31346162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A specific JMJD6 inhibitor potently suppresses multiple types of cancers both in vitro and in vivo.
    Xiao RQ; Ran T; Huang QX; Hu GS; Fan DM; Yi J; Liu W
    Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2200753119. PubMed ID: 35969736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
    Rathert P; Roth M; Neumann T; Muerdter F; Roe JS; Muhar M; Deswal S; Cerny-Reiterer S; Peter B; Jude J; Hoffmann T; Boryń ŁM; Axelsson E; Schweifer N; Tontsch-Grunt U; Dow LE; Gianni D; Pearson M; Valent P; Stark A; Kraut N; Vakoc CR; Zuber J
    Nature; 2015 Sep; 525(7570):543-547. PubMed ID: 26367798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms.
    Shi X; Mihaylova VT; Kuruvilla L; Chen F; Viviano S; Baldassarre M; Sperandio D; Martinez R; Yue P; Bates JG; Breckenridge DG; Schlessinger J; Turk BE; Calderwood DA
    Proc Natl Acad Sci U S A; 2016 Aug; 113(31):E4558-66. PubMed ID: 27432991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia.
    Romine KA; Nechiporuk T; Bottomly D; Jeng S; McWeeney SK; Kaempf A; Corces MR; Majeti R; Tyner JW
    Blood Cancer Discov; 2021 Sep; 2(5):518-531. PubMed ID: 34568834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
    Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
    Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disruption of CTCF Boundary at HOXA Locus Promote BET Inhibitors' Therapeutic Sensitivity in Acute Myeloid Leukemia.
    Zha J; Lai Q; Deng M; Shi P; Zhao H; Chen Q; Wu H; Xu B
    Stem Cell Rev Rep; 2020 Dec; 16(6):1280-1291. PubMed ID: 33057942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Wnt3a/β-catenin/TCF7L2 signaling axis reduces the sensitivity of HER2-positive epithelial ovarian cancer to trastuzumab.
    Shen G; Gao Q; Liu F; Zhang Y; Dai M; Zhao T; Cheng M; Xu T; Jin P; Yin W; Huang D; Weng H; Chen W; Ren H; Mu X; Wu X; Hu S
    Biochem Biophys Res Commun; 2020 Jun; 526(3):685-691. PubMed ID: 32248976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL.
    Bauer K; Hauswirth A; Gleixner KV; Greiner G; Thaler J; Bettelheim P; Filik Y; Koller E; Hoermann G; Staber PB; Sperr WR; Keil F; Valent P
    Am J Hematol; 2024 Sep; 99(9):1721-1731. PubMed ID: 38822666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BET Inhibitors Potentiate Chemotherapy and Killing of
    Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
    Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.
    Liao S; Maertens O; Cichowski K; Elledge SJ
    Genes Dev; 2018 Sep; 32(17-18):1188-1200. PubMed ID: 30135075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells.
    Xie C; Pan Y; Hao F; Gao Y; Liu Z; Zhang X; Xie L; Jiang G; Li Q; Wang E
    APMIS; 2014 Dec; 122(12):1251-8. PubMed ID: 25131138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
    Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
    Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 40. KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity.
    Qiang Y; Fan J; Xie C; Yan L; Song X; Zhang N; Lin Y; Xiong J; Zhang W; Liu Y; Wei L; Li Y; Chen S; Liang K; Li F
    Cancer Res; 2024 Apr; 84(8):1252-1269. PubMed ID: 38285760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.